University of Maryland Medicine, the joint enterprise of the University of Maryland School of Medicine, the University of Maryland Medical Center, and University of Maryland Medical System, today launched a landmark initiative called My Healthy Maryland Precision Medicine Research. The project aims to enroll 250,000 Maryland residents over the next decade who reflect the diversity of the state and want to play a pivotal role in helping researchers understand how genes and lifestyle affect an individual’s health.
Gain Therapeutics made its debut on the Nasdaq Thursday with a $40 million initial public offering. The company will use the funds to advance the development of its pipeline of therapeutics for rare genetic diseases characterized by protein misfolding.
Gain Therapeutics and the University of Maryland School of Medicine forged a research collaboration to investigate Gain’s structurally targeted allosteric regulators (STARs) in cellular models of neuronopathic Gaucher disease (nGD) and Parkinson’s disease (PD).
UMB’s Microbial Genomics Trailblazer Claire M. Fraser Named AAAS President-Elect Claire M. Fraser will become the next president-elect of AAAS in February. | Tom Jemski/University of Maryland School of Medicine [….]